In contrast, recent evidence has shown that failure of therapeutic response to IFN-β in RRMS patients is associated with a Th17 phenotype (20, 25) and that this treatment is ineffective, or can even worsen, other Th17-mediated autoimmune disorders, such as NMO and psoriasis (55). This evidence concerns the gene IFNB1 and psoriasis.